1053656-51-1

Basic information

• Product Name: 5-tert-butyl 2-ethyl 6,7-dihydrothiazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate
• Synonyms: 5-tert-butyl 2-ethyl 6,7-dihydrothiazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate;6,7-Dihydrothiazolo[5,4-c]pyridine-2,5(4H)-dicarboxylic acid 5-(tert-butyl) 2-ethyl ester;Ethyl 5-Boc-4,5,6,7-tetrahydro-1,3-thiazolo[5,4-c]pyridine-2-carboxylate;5-tert-butyl 2-ethyl 4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridine-2,5-dicarboxylate;Ethyl 5-Boc-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylate;5-tert-Butyl 2-ethyl 6,7-dihydrothiazolo[5,4-c]pyridine-2,5(4H)
• CAS NO: 1053656-51-1
• Molecular Formula: C₁₄H₂₀N₂O₄S
• Molecular Weight: 312.3846
• Product Categories: CHIRAL CHEMICALS
• Mol File: 1053656-51-1.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 429.0±55.0 °C(Predicted)
• Appearance: /
• Density: 1.241
• Storage Temp.: 2-8°C
• PKA: 0.72±0.20(Predicted)
• CAS DataBase Reference: 5-tert-butyl 2-ethyl 6,7-dihydrothiazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 5-tert-butyl 2-ethyl 6,7-dihydrothiazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate(1053656-51-1)
• EPA Substance Registry System: 5-tert-butyl 2-ethyl 6,7-dihydrothiazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate(1053656-51-1)

Safety Data

• Hazardous Substances Data: 1053656-51-1(Hazardous Substances Data)

Usage

General Description

5-tert-butyl 2-ethyl 6,7-dihydrothiazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate is a chemical compound with the molecular formula C19H25NO4S. It is a thiazolidine derivative with potential anti-inflammatory and analgesic properties. The compound acts as a modulator of G-protein coupled receptors, specifically the nociception receptor, which is involved in the transmission and modulation of pain. It has been studied for its potential use in the treatment of inflammatory and neuropathic pain conditions. However, further research is necessary to fully understand its therapeutic potential and possible side effects.

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 758685-72-2 5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-carboxylic acid 
• 1135122-10-9 ethyl 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylate 
• 1598386-43-6 4-(2-(5-carbamimidoyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carbonyl)-5-(4-methoxypiperidin-1-yl)-1 ,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid trifluoroacetate 
• 1186663-33-1 C₉H₁₂N₂O₂S*ClH 

Relevant articles and documents

Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors

Factor Xa (fXa) is a crucial player in various thromboembolic disorders. Inhibition of fXa can provide safe and effective antithrombotic effects. In this study, a series of anthranilamide compounds were designed by utilizing structure-based design strategies. Optimization at P1 and P4 groups led to the discovery of compound 16g: a highly potent, selective fXa inhibitor with pronounced in vitro anticoagulant activity. Moreover, 16g also displayed excellent in vivo antithrombotic activity in the rat venous thrombosis (VT) and arteriovenous shunt (AV-SHUNT) models. The bleeding risk evaluation showed that 16g had a safer profile than that of betrixaban at 1 mg/kg and 5 mg/kg dose. Additionally, 16g also exhibited satisfactory PK profiles. Eventually, 16g was selected to investigate its effect on hypoxia-reoxygenation- induced H9C2 cell viability. MTT results showed that H9C2 cell viability can be remarkably alleviated by 16g.